AI Article Synopsis
- ALSUntangled examines alternative treatments for ALS, focusing on psilocybin, a psychedelic compound from mushrooms.
- Psilocybin may theoretically help slow ALS due to its ability to cross the blood-brain barrier and influence neurogenesis and inflammation, but there's no existing research specifically on its effects in ALS patients.
- Due to potential risks of psychological side effects and lack of supporting evidence, the use of psilocybin for ALS progression is not currently endorsed.
Article Abstract
ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no pre-clinical ALS models, case reports, or trials for psilocybin and ALS in the context of disease modifying therapy. Depending on dosing, there can be a high risk of psychological side effects including hallucinations and physical harm. Based on the above information, we do not currently support the use of psilocybin as a means to slow ALS progression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21678421.2024.2441274 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!